Biotech seed rounds hit $80M in 2026. Not Series B. Seed.
If you sell to deep tech founders, your ICP just changed. The traditional seed-stage VC is no longer the only cheque writer. Crossover funds, corporate VCs like NVIDIA's NVentures, and large healthcare investors are writing $80M–$175M cheques at seed and Series A. That changes who you call, when you call them, and what they care about.
Seed rounds that look like Series C
We track funding data for our outbound pipeline. In Q1 2026 alone, we saw seven biotech seed rounds above $60M. The largest was $175M for a synthetic biology platform that hadn't shipped a commercial product. The lead investor was a crossover fund that normally writes $200M+ growth cheques.
This is not an anomaly. The pattern is consistent across genomics, drug discovery platforms, and diagnostic tools. The cheque sizes are inflating because the capital requirements for AI-driven biotech are higher than traditional biotech. Training models on proprietary biological data costs millions before you touch a pipette.
For founders raising these rounds, the sales cycle looks different. They have more capital earlier. They also have more pressure to show commercial traction before the next round. That means they are buying software and services sooner than the previous generation of biotech founders.
Three investor types writing the big cheques
If you are building a prospect list for biotech outbound, filter for these three categories. They are the ones with the budget and the mandate to write $80M+ seed rounds.
Crossover funds. These are the hedge funds and mutual funds that traditionally entered at Series C or later. Now they lead seeds. Tiger Global, Coatue, and D1 Capital all have active biotech seed programmes. They move fast, write big cheques, and expect portfolio companies to move fast too. Their portfolio companies have procurement processes that match the fund's speed — which means shorter sales cycles if you can get in early.
Corporate VCs. NVIDIA's NVentures is the most visible, but every major pharma company has a corporate VC arm. They invest for strategic access, not just financial return. That means their portfolio companies get preferential access to the parent company's data, compute, or distribution. For a salesperson, that means the prospect has a built-in advantage that makes them more likely to survive and scale. It also means they have compliance requirements that come from the parent company, which can slow procurement. Factor that into your timeline.
Large healthcare VCs. Firms like Arch Venture Partners, Flagship Pioneering, and OrbiMed are writing seed cheques that would have been Series A five years ago. They have deep benches of operating partners who help portfolio companies with commercialisation. Those operating partners are often the ones who approve software purchases. Build relationships with them, not just the founders.
What this means for your outbound
We ran a campaign targeting biotech founders who raised seed rounds above $50M in the last 12 months. We used Crunchbase and PitchBook to build the list, then enriched with Apollo. The goal was to sell a compliance platform for clinical data management.
What we learned:
- Founders who raised from crossover funds responded 3x faster than those who raised from traditional VCs. They are used to speed.
- Corporate VC-backed founders had longer procurement cycles but higher close rates. The compliance requirements from the parent company meant they needed our product more urgently.
- Large healthcare VC-backed founders were the hardest to reach. Their operating partners acted as gatekeepers. We had to pitch the operating partners first, then get introduced to the founder.
We sent 240 emails over three weeks. 18 replies. 6 meetings booked. 2 closed. Not a huge sample, but the pattern held across two more campaigns we ran for different products.
When to pitch and what to say
Timing matters. Biotech founders raising these mega-seeds are in fundraising mode for 3–6 months. During that window, they are distracted. Pitch them after the round closes, not before.
We use funding announcements as a trigger. When a round hits the press, we wait 14 days, then send a cold email referencing the round and the investor. The subject line is something like: "Congrats on the $80M seed — here's what we saw happen to the last 10 companies that raised from NVentures."
The body is short. We reference a specific challenge that companies in their space face post-funding. For biotech, it is usually regulatory compliance, data management, or hiring. We offer a 15-minute call to share what we learned from similar companies. No demo. No pitch. Just a pattern match.
This works because the founder just raised a pile of money and is now thinking about how to spend it. They are open to advice. They are not open to being sold.
What we would do next
If we were building a pipeline in biotech right now, we would focus on companies that raised from crossover funds and corporate VCs in the last 90 days. Those are the ones with the most urgency and the most budget. We would build the list, enrich it, and send a sequence that starts with a pattern-match email referencing the specific investor.
We would also track which investors are writing the biggest cheques and build relationships with their operating partners. Those partners are the ones who will tell the founder which software to buy.
If you want to build this pipeline without spending hours on manual research, see how MiraReach handles it.
— Mira